Bristol-Myers Squibb (NYSE:BMY) recently gained European Commission approval for Breyanzi, broadening treatment options for ...

We recently published a list of Friday’s 10 Worst Performing Stocks. In this article, we are going to take a look at where ...

William Blair upped their Q2 2025 earnings estimates for Bristol-Myers Squibb in a note issued to investors on Tuesday, March ...

Bristol Myers Squibb will acquire 2seventy bio for about $286 million in cash, sending the cancer cell therapy maker's shares ...

Multiple myeloma cell therapy Abecma is the lone remaining asset of 2seventy Bio, which spun out from Bluebird Bio ...

Bristol-Myers Squibb acquires 2seventy bio for $286M, marking the end of a once-promising biotech. Check out if this is a ...

Princeton: Bristol Myers Squibb has announced that the European Commission (EC) has granted approval to Breyanzi ...

This was the stock's second consecutive day of losses.

Three months after Bristol Myers Squibb revealed the success of two phase 3 trials of its oral targeted therapy Sotyktu in ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ascend Wellness Holdings LLC (AAWH – Research ...

EC approves BMY's Breyanzi for relapsed or refractory FL, based on Phase 2 study showing high response rates & sustained ...

Abecma is being jointly developed and commercialized in the U.S. as part of a co-development, co-promotion, and profit share ...